Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent Influenza Vaccine (Split Virion), Inactivated Phase III Trial in ≥3-Year-Olds
CTR20221439Phase 3Completed
- Sponsor
- Tianyuan Bio-Pharmaceutical
- Start
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quadrivalent influenza vaccine in seasonal influenza (2 arms), sponsored by Tianyuan Bio-Pharmaceutical. Primary endpoints: Immunogenicity non-inferiority: GMT ratio and seroconversion rate difference and Safety: solicited and unsolicited adverse events and serious adverse events. Started Jun 2022; status: completed.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on CTR20221439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221439.